Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.38 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29597907 | 0.64 | LRRK2 (0.38) | CNR2F2RL1MAP3K12 | |
| SCHEMBL22023291 | 0.64 | LRRK2 (0.38) | CNR2F2RL1MAP3K12 | |
| SCHEMBL22236238 | 0.64 | GRIN2D (0.47) | PDE10ADPP4 | |
| SCHEMBL28590337 | 0.64 | POLB (0.55) | CNR2DPP4 | |
| SCHEMBL29225192 | 0.61 | HRH3 (0.43) | CNR2PDE10A | |
| SCHEMBL30486010 | 0.61 | EP300 (0.43) | MAP3K12SYK | |
| SCHEMBL29039125 | 0.61 | EP300 (0.43) | MAP3K12SYK | |
| SCHEMBL30667429 | 0.60 | KEAP1 (0.52) | CNR2F2RL1PDE10APDE3BPDE3A | |
| SCHEMBL30637430 | 0.59 | SORD (0.47) | MAP3K12PDE10ADPP4 | |
| SCHEMBL30471929 | 0.58 | CHRNB2 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| WO-2021083380-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, CYP4A11, HSD11B1 | CNR2 3520/4885F2RL1 1854/4885CNR1 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.